131 related articles for article (PubMed ID: 36627051)
1. Efficacy and safety of HER2-targeted therapy in patients with colorectal cancer: What should we expect from a meta-analysis?
Wang M; Su J; Lu J; Yang Z; Wang J; Zhong Y; Zeng T; Shen K; Lin S
Clin Res Hepatol Gastroenterol; 2023 Feb; 47(2):102078. PubMed ID: 36627051
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of HER2-targeted inhibitors for metastatic colorectal cancer with HER2-amplified: A meta-analysis.
Gao M; Jiang T; Li P; Zhang J; Xu K; Ren T
Pharmacol Res; 2022 Aug; 182():106330. PubMed ID: 35781058
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of immune checkpoint inhibitors in colorectal cancer: a systematic review and meta-analysis.
Zeng T; Fang X; Lu J; Zhong Y; Lin X; Lin Z; Wang N; Jiang J; Lin S
Int J Colorectal Dis; 2022 Jan; 37(1):251-258. PubMed ID: 34716473
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis.
Li Z; Guo S; Xue H; Li L; Guo Y; Duan S; Zhu H
Front Pharmacol; 2023; 14():1183514. PubMed ID: 37426807
[No Abstract] [Full Text] [Related]
5. A Meta-Analysis to Assess the Efficacy of HER2-Targeted Treatment Regimens in HER2-Positive Metastatic Colorectal Cancer (mCRC).
Chitkara A; Bakhtiar M; Sahin IH; Hsu D; Zhang J; Anamika F; Mahnoor M; Ahmed R; Gholami S; Saeed A
Curr Oncol; 2023 Sep; 30(9):8266-8277. PubMed ID: 37754515
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, advanced breast cancer: a systematic review and meta-analysis.
Dai Q; Wang Y; Liao M; Chen H
Ann Palliat Med; 2022 Dec; 11(12):3727-3742. PubMed ID: 36635998
[TBL] [Abstract][Full Text] [Related]
7. Overall survival and progression-free survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials.
Tian Q; Gao H; Zhou Y; Yang J
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7252-7267. PubMed ID: 34919224
[TBL] [Abstract][Full Text] [Related]
8. Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis.
Ter Veer E; van den Ende T; Creemers A; de Waal L; van Oijen MGH; van Laarhoven HWM
Acta Oncol; 2018 Dec; 57(12):1599-1604. PubMed ID: 30264641
[TBL] [Abstract][Full Text] [Related]
9. Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors.
Wang J; Zhang B; Cheng X; Li Q; Lv H; Nie C; Chen B; Xu W; Zhao J; He Y; Tu S; Chen X
J Oncol; 2022; 2022():4233782. PubMed ID: 35368895
[TBL] [Abstract][Full Text] [Related]
10. Oral versus intravenous fluoropyrimidines for colorectal cancer.
Chionh F; Lau D; Yeung Y; Price T; Tebbutt N
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD008398. PubMed ID: 28752564
[TBL] [Abstract][Full Text] [Related]
11. HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trials.
Li X; Wu S; Zhang L; Zhu J; Xu B
Ann Transl Med; 2020 Dec; 8(24):1634. PubMed ID: 33490146
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials.
Liang RF; Zheng LL
Drug Des Devel Ther; 2015; 9():4471-8. PubMed ID: 26300630
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis.
Kawalec P; Łopuch S; Mikrut A
Clin Breast Cancer; 2015 Apr; 15(2):90-100.e1. PubMed ID: 25441421
[TBL] [Abstract][Full Text] [Related]
14. Studies on the Safety and Efficacy of Pyrotinib in the Treatment of HER2- Positive Advanced Solid Tumors Excluding Breast Cancer.
Yin Y; Yang H; Liu Z; Tan J; Zhu C; Chen M; Zhou R; Wang L; Qian J
Cancer Manag Res; 2020; 12():13479-13487. PubMed ID: 33408520
[TBL] [Abstract][Full Text] [Related]
15. Outcome of Molecular Targeted Agents Plus Chemotherapy for Second-Line Therapy of Metastatic Colorectal Cancer: A Meta-Analysis of Randomized Trials.
Pei X; Liu Y; Sun L; Zhang J; Fang Y; Liao X; Liu J; Zhang C; Yin T
Clin Colorectal Cancer; 2016 Dec; 15(4):e149-e156. PubMed ID: 27155750
[TBL] [Abstract][Full Text] [Related]
16. Second-line systemic therapy for metastatic colorectal cancer.
Mocellin S; Baretta Z; Roqué I Figuls M; Solà I; Martin-Richard M; Hallum S; Bonfill Cosp X
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD006875. PubMed ID: 28128439
[TBL] [Abstract][Full Text] [Related]
17. Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials.
Khattak MA; Martin H; Davidson A; Phillips M
Clin Colorectal Cancer; 2015 Jun; 14(2):81-90. PubMed ID: 25666296
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis.
Li Y; Du Y; Xue C; Wu P; Du N; Zhu G; Xu H; Zhu Z
BMC Gastroenterol; 2022 Oct; 22(1):431. PubMed ID: 36217119
[TBL] [Abstract][Full Text] [Related]
20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]